Bruce Meiklejohn

Bruce Meiklejohn is a principal fellow, regulatory COE-biotech at Eli Lilly and Company

Articles

Quality by Design for Biotechnology Products—Part 3

Regulatory flexibility can make continuous improvement possible.

Quality by Design for Biotechnology Products—Part 2

Second in a three-part series that discusses the complexities of QbD implementation in biotech development.

Quality by Design for Biotechnology Products—Part 1

First in a three-part series that discusses the complexities of QbD implementation in biotech product development.